Highlights Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
5.02 ^USD	-2.90%		-1.57%	-44.16%

07/05	Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value	CI
02/05	Transcript : Aurinia Pharmaceuticals Inc., Q1 2024 Earnings Call, May 02, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q1 Revenue $50.3M, vs. Street Est of $47.1M	02/05	MT
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Aurinia Pharmaceuticals Inc. Reiterates Revenue Guidance for the Fiscal Year 2024	02/05	CI
Aurinia Pharmaceuticals Inc. Announces The U.S. Food & Drug Administration Approves Updated LUPKYNIS® Label to include Long-Term Data from the AURORA Clinical Program	30/04	CI
Aurinia Pharmaceuticals Q4 Loss Widens, Revenue Increases; Concludes Strategic Review -- Shares Slump	15/02	MT
Aurinia Pharmaceuticals Inc. announces an Equity Buyback for $150 million worth of its shares.	15/02	CI
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q4 Revenue $45.1M, vs. Street Est of $45.2M	15/02	MT
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/02	CI
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02	CI
Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2024	15/02	CI
AURINIA PHARMACEUTICALS FINDS NO BUYER, TO ANNOUNCE $1…	15/02	RE
Kidney drug developer Aurinia fails to clinch a sale, sources say	15/02	RE
Aurinia Pharmaceuticals Inc. authorizes a Buyback Plan.	15/02	CI
Aurinia Pharmaceuticals Reports Higher Q4, 2023 Preliminary Revenue; Shares Rise	05/01	MT
Aurinia Pharmaceuticals Submits Investigational New Drug Application for AUR200	20/12	MT
Aurinia Pharmaceuticals Inc. Submits IND Application to US Food & Drug Administration for AUR 200	20/12	CI
Aurinia Pharmaceuticals Partner Otsuka Pharmaceutical Files New Drug Application For Voclosporin in Japan	13/11	MT
Aurinia Pharmaceuticals Inc. Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS for Managing Lupus Nephritis	03/11	CI
Aurinia Pharmaceuticals Inc. Provides Earnings Guidance for the Fiscal Year 2023	02/11	CI
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q3 Revenue $54.5M, vs. Street Est of $38.5M	02/11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Highlights

Filters